Stockhead on MSN

Health check: Telix jumps first hurdle with its advanced prostate cancer therapy trial

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...

Why is this ASX 200 share charging 7% higher today?

This stock is making its shareholders smile on Tuesday. Let's find out why. The post Why is this ASX 200 share charging 7% higher today? appeared first on The Motley Fool Australia.

John Tesh, 73, reveals how he survived rare form of prostate cancer after being given just 18 months to live

Former ET co-host John Tesh revealed he that he far exceeded the wildest expectations of doctors who diagnosed him with cancer more than a decade ago - but he still lives with the disease.
The Manila Times

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Canc…

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...